Trial Profile
Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 15 Dec 2015 New trial record